Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1.
Shu-Ting TanVeronica BoyleMarianne S ElstonPublished in: Hypertension (Dallas, Tex. : 1979) (2023)
Major gaps in the literature around FH1 patients' long-term treatment and disease outcomes still exist. Long-term outcome data are required to help inform clinicians of the best long-term treatment for FH1.
Keyphrases